# An observational study to investigate whether fatigue is a side effect of etanercept in patients with moderate to severe psoriasis.

No registrations found.

**Ethical review** Positive opinion

**Status** Recruiting

Health condition type -

**Study type** Observational non invasive

# **Summary**

#### ID

NL-OMON28989

#### Source

Nationaal Trial Register

#### **Brief title**

N/A

#### **Health condition**

- 1. Fatigue (moeheid);
- 2. Psoriasis.

## **Sponsors and support**

**Primary sponsor:** Academic Medical Center (AMC), Department of Dermatology

Source(s) of monetary or material Support: N/A

#### Intervention

#### **Outcome measures**

#### **Primary outcome**

The results of fatigue specific questionnaires.

# **Study description**

#### **Background summary**

We have noticed that patients who are treated with etanercept for moderate to severe plaque type psoriasis remarkably often spontaneously report fatigue as adverse event. However, fatigue is not a known adverse event of etanercept and data in the literature are not univocal. Therefore, we have designed this pilot study to objectify whether fatigue is an adverse event of etanercept. Fatigue specific questionnaires are completed at week 0, week 6 and week 12 of treatment. At these moments blood and urine will be analysed to reveal some common disease that are known to cause fatigue. The same study procedures will be carried out in a comparable group of patients who start witj UVB therapy.

#### Study objective

Our hypothesis is that although treatment with etanercept improves the psoriasis and thereby the quality of lives in most people who are treated, in some people fatigue occurs as adverse event.

#### Intervention

None, this is an observational study.

## **Contacts**

#### **Public**

Meibergdreef 9, L.L.A. Lecluse Amsterdam 1105 AZ The Netherlands ++31 20 5662530 **Scientific** Meibergdreef 9, L.L.A. Lecluse Amsterdam 1105 AZ The Netherlands ++31 20 5662530

# **Eligibility criteria**

#### Inclusion criteria

- 1. Patients who start with etanercept or UVB therapy (control group) for psoriasis.
- 2. Patients who have a PASI > or = 10.

#### **Exclusion criteria**

- 1. Patients who have another active disease which is known to cause fatigue;
- 2. Patients who use therapeuticals which are known to cause fatigue;
- 3. Unability to comply with study procedures, like filling in questionnaires in Dutch.

# Study design

## **Design**

Study type: Observational non invasive

Intervention model: Parallel

Control: N/A, unknown

#### Recruitment

NL

Recruitment status: Recruiting

Start date (anticipated): 30-10-2006

Enrollment: 30

Type: Anticipated

## **Ethics review**

Positive opinion

Date: 19-09-2007

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register ID

NTR-new NL1042 NTR-old NTR1075 Other : incomplete

ISRCTN wordt niet meer aangevraagd

# **Study results**

### **Summary results**

N/A